Biotechnology
- 708.254
- -0.981-0.14%
INNOCARE collaborates with Cannovia "NewCo" for international expansion, potentially receiving over $0.5 billion in milestone payments.
① INNOCARE and Kangnuoya will collectively receive an initial and recent payment of 17.5 million USD at a ratio of 50% each, and will also acquire minority shares in Prolium; ② In recent years, the NewCo model trade boom has emerged, which has dual attributes of financing and business development, providing innovative drug companies with an alternative path to go abroad, apart from the traditional license out.
The small molecule new drug has exceeded 1 billion, and the large molecule dual antibody has achieved authorization overseas.
On January 16, 2025, INNOCARE (Shanghai Stock Exchange code: 688428; Hong Kong Stock Exchange code: 09969) released the annual performance forecast for 2024, ending December 31, 2024.
Market Overview | The Hong Kong stock market continues to rise! The Hang Seng Index once returned to the 0.02 million point mark, Network Technology stocks advanced strongly, with JD.com, Meituan, and Alibaba all rising over 5%.
Futu News reported on January 20 that Hong Kong stocks opened higher and continued to rise, with the Hang Seng Index aiming for 0.02 million points, and the Hang Seng TECH Index once rising over 3%.
Express News | Hong Kong stocks in the Biomedical sector collectively rose, with WUXI APPTEC increasing by over 5%.
The domestic sales of the flagship products have increased significantly, and R&D expenses have decreased by thirty percent. JUNSHI BIO expects losses to narrow by more than forty percent in 2024.
① JUNSHI BIO also announced that Toripalimab has been approved for marketing by the Australian Therapeutic Goods Administration, and this drug will become the first and only tumor immunotherapy drug for nasopharyngeal carcinoma in Australia. ② Regarding the reasons for revenue growth, JUNSHI BIO explained that it is mainly due to the increase in sales revenue of commercialized Pharmaceuticals compared to the same period last year. As of the end of the reporting period, the company has four commercialized Pharmaceuticals.
The US stock market fluctuated and then declined, Apple fell by 4%, Taiwan Semiconductor's ADR once rose over 7%, and Luxury Goods stocks along with European and American government bonds increased.
In December, USA's retail sales growth was weaker than expected, but the Philadelphia January manufacturing Index reached its highest level in nearly four years. Federal Reserve Board member Waller predicted that there might be up to four interest rate cuts this year, which lowered USA Treasury yields and the dollar. The S&P experienced its first decline in four days, previously boosted by Banks' Earnings Reports. Taiwan Semiconductor's quarterly report confirmed AI demand, leading to most chip stocks rising. Luxury Goods giant Richemont's earnings surpassed expectations, causing a collective increase among peers that pushed French stocks up over 2%. The China concept index rose against the trend, with DouYu increasing by about 28%. The yen approached 155, Bitcoin hovered around $0.1 million, oil prices fell from a six-month high, and Gold reached its highest in five weeks. As a cold wave hit, Henry Hub Natural Gas surged over 4%.
Sales growth of core varieties: REMEGEN's revenue in 2024 is expected to increase by more than 50% year-on-year, but it has not yet achieved profitability.
① The company has increased its R&D investment, while sales revenue of Tai Tasi Pu and Vidi Situt Monoclonal Antibody has grown rapidly, with the product gross margin continuing to rise and the sales expense ratio significantly decreasing. Therefore, it is expected that the company will report a net loss in 2024, showing a trend of reduced losses; ② The company's Phase III clinical trial for IgAN of Tai Tasi Pu in China has concluded, and data readout is expected in the first half of 2025.
Zai Lab to Seek China Approval for Cervical Cancer Therapy After Positive Trial Data
WUXI XDC's net income for 2024 is expected to increase by 260%. WUXI APPTEC recently cashed out 2.4 billion Hong Kong dollars at a high point | Quick read of the announcement.
In 2024, WUXI XDC expects full-year revenue, Net income, and adjusted Net income to increase by more than 85%, 260%, and 170% year-on-year respectively; According to the latest data from Frost & Sullivan, it is expected that by 2030, the Global market size of ADC and XDC will reach 66.2 billion dollars.
In 2025, operating profit is expected to turn positive. The "big brother" of the Star pharmaceutical sector issues "red envelopes" as stock prices soar in both AH markets.
① The company's CEO, Mr. O Lei Qiang, introduced the business's recent status, the pipeline layout in the fields of hematological tumors and solid tumors, as well as future development plans and expected progress at the 43rd JPMorgan Annual Medical Health Conference. ② BEIGENE's adjusted operating profit for the third quarter is 65.63 million USD, achieving non-GAAP (Generally Accepted Accounting Principles in the USA) operating profit for two consecutive quarters.
Express News | Hong Kong stocks in the Biomedical sector surged, with BEIGENE rising nearly 7%, WUXI BIO and WUXI APPTEC both increasing by over 4%, and TIGERMED gaining nearly 3%.
Take action again! WUXI APPTEC sells 7.17% of WUXI XDC Stocks | Quick read of the announcement.
① The Stocks sold by WUXI APPTEC account for about 7.17% of the current total share capital of WUXI XDC, with a cumulative transaction amount of approximately 2.426 billion Hong Kong dollars; ② This is the second time WUXI APPTEC has recently sold related Assets; ③ WUXI XDC's revenue for the first half of 2024 increased by 67.6% year-on-year.
This week, an additional 29 companies have announced! TIGERMED and several other stocks disclosed repurchase and shareholding refinancing plans, with a list of related A-shares overview.
① The number of A-share listed companies receiving special loan support continues to expand. According to incomplete Statistics, as of the time of writing, 29 listed companies have disclosed information related to share repurchase and increased shareholding for re-loan this week (see attached table); ② TIGERMED received the highest amount of special loan support, totaling no more than 0.7 billion yuan.
An alternative "going abroad" for centralized procurement of pharmaceuticals and medical devices? The China-ASEAN regional centralized procurement platform for pharmaceuticals has been launched, and the industry anticipates the birth of the first Order.
① Today, the China-ASEAN pharmaceutical regional procurement platform officially launched, with representatives from Shenzhen Mindray Bio-Medical Electronics, United Imaging Healthcare, SIMCERE PHARMA, and other companies present; ② Although the specific implementation plan is yet to be clarified, the industry believes it is undoubtedly Bullish for domestic pharmaceutical companies; ③ The Southeast Asian pharmaceutical market is growing rapidly, but it relies heavily on imported drugs and medical devices.
INNOCARE: Tansanitumumab combined with lenalidomide has been approved in Macau for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
China Securities Network News (Wang Luo) On January 8, INNOCARE announced on its WeChat public account that tanzilumab combined with lenalidomide has been approved in Macau for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
WUXI BIO has once again divested overseas Assets! Merck takes over WUXI BIO's Ireland vaccine factory for 0.5 billion USD | Quick read announcement.
① WUXI BIO announced today that it will sell the Ireland vaccine factory to Merck for 0.5 billion USD; ② this vaccine factory was originally built to undertake Merck's vaccine contract manufacturing business; ③ not long ago, WUXI APPTEC also divested its WuXi ATU business in the USA and United Kingdom.
So sudden! What happened with the well-known Hong Kong stocks in a collective turmoil?
In today's morning session, the Hong Kong stock market suddenly experienced a significant decline, with all three major Indexes dropping by more than 2%.
Not just a simple "split": The multifaceted considerations behind the sale of WUXI APPTEC's CGT Business.
In an era where Globalization and protectionism coexist, the rapid iteration of cutting-edge technologies, alongside multiple constraints from policies and capital, poses unprecedented challenges for pharmaceutical innovation companies.
Selling ATU's USA and United Kingdom Business, the strategy behind WUXI APPTEC.
There is gain in loss.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.